סימבקסון 10

Country: ইস্রায়েল

ভাষা: হিব্রু

সূত্র: Ministry of Health

সক্রিয় উপাদান:

SIMVASTATIN

থেকে পাওয়া:

DEXCEL PHARMA TECHNOLOGIES LTD

এটিসি কোড:

C10AA01

ফার্মাসিউটিকাল ফর্ম:

קפליות

রচনা:

SIMVASTATIN 10 MG

প্রশাসন রুট:

פומי

প্রেসক্রিপশন টাইপ:

מרשם נדרש

Manufactured by:

DEXCEL LTD, ISRAEL

Therapeutic group:

SIMVASTATIN

Therapeutic area:

SIMVASTATIN

থেরাপিউটিক ইঙ্গিত:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvaxon is indicated to: - Reduce the risk of total mortality by reducing coronary death - Reduce the risk of non-fatal myocardial infarction - Reduce the risk for undergoing myocardial revascularization procedures - Reduce the risk of stroke and transient ischemic attacks (TIA's). Hyperlipidemia: Simvaxon is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia ( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvaxon therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvaxon is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hype

পণ্য সারাংশ:

Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Pravastatin, Simvastatin

অনুমোদন তারিখ:

2020-04-30